Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOBID vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP, and blocking adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity,Off-label: Adjuvant in treatment of obstructive sleep apnea
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
Theophylline extended-release capsules: 300-600 mg/day orally divided every 12 hours. Initial dose 300 mg/day, titrate based on serum concentrations (target 10-20 mcg/m L). Max 600 mg/day unless serum levels monitored.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Neonates: 24-36 h; Children (1-9 y): 3-4 h; Adults (non-smokers): 6-12 h; Adults (smokers): 4-5 h; Hepatic cirrhosis: prolonged (up to 30 h); Heart failure: prolonged (up to 20 h).
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Primarily hepatic via CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Exhibits saturable (nonlinear) pharmacokinetics at high doses.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Renal (10% unchanged), hepatic metabolism (90%, primarily via CYP1A2 and CYP3A4); 20% excreted in feces as metabolites.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
40-60% (primarily to albumin). Decreased binding in neonates, hepatic disease, and uremia.
65% bound to albumin
0.45 L/kg (range: 0.3-0.7 L/kg). Higher in neonates (0.7-0.9 L/kg). Represents distribution throughout total body water.
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral: 96-100% (immediate release); Sustained release (THEOBID): ~100% (bioequivalent to immediate release at steady state); IV: 100%; Rectal: ~80-100%.
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
No specific GFR-based dose adjustment for theophylline. However, accumulation may occur in severe renal impairment; monitor serum levels and adjust dose to achieve therapeutic concentrations (10-20 mcg/m L).
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Child-Pugh Class A: Reduce dose by 50%. Child-Pugh Class B or C: Reduce dose by 75% or use alternative. Monitor serum concentrations closely.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
For asthma: Oral immediate-release: 5 mg/kg/day divided q6-8h. Extended-release: 10-20 mg/kg/day divided q12h (max 600 mg/day). Target serum concentration 5-15 mcg/m L. Dosing based on age and weight, titrate slowly.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Elderly patients (>60 years) often have reduced clearance. Start with 300 mg/day orally extended-release, titrate slowly to lowest effective dose. Monitor serum concentrations closely to avoid toxicity (target 5-15 mcg/m L).
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
No FDA black box warning.
No FDA black box warning.
Risk of serious cardiovascular toxicity (arrhythmias, seizures, death) especially at serum levels >20 mcg/m L,Cautious use in patients with peptic ulcer, seizure disorders, cardiac disease, hepatic impairment,Monitor serum theophylline levels to avoid toxicity,Reduce dose in smokers and with drugs that induce CYP1A2 (e.g., phenytoin, rifampin),Avoid in patients with active peptic ulcer or uncontrolled seizure disorders
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to theophylline or any component of the formulation,Active peptic ulcer disease,Uncontrolled seizure disorders
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
High-fat meals can increase absorption of sustained-release formulations. Charcoal-broiled foods and a high-protein, low-carbohydrate diet can increase theophylline clearance. Avoid concurrent ingestion of caffeine-containing foods/beverages.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
Theophylline (THEOBID) is not considered a major teratogen. First trimester: Limited data show no significant increase in congenital malformations. Second and third trimesters: No known structural effects; fetal tachycardia and irritability may occur due to maternal toxicity. Neonatal withdrawal (jitteriness, vomiting) reported with third-trimester use.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels may reach therapeutic concentrations, especially in preterm neonates. Risk of irritability, jitteriness, and feeding problems. Benefit of breastfeeding should be weighed against potential adverse effects; monitor infant for theophylline toxicity.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
Pregnancy increases theophylline clearance due to elevated cardiac output and increased hepatic metabolism, particularly in the second and third trimesters. Dose may need to be increased by 30-50% to maintain therapeutic levels. Postpartum, clearance decreases; dose should be reduced to prepregnancy levels within 2 weeks to avoid toxicity. Monitor serum levels and adjust accordingly.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
Theophylline levels must be monitored; narrow therapeutic index (5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders. Use with caution in heart failure, hepatic impairment, and elderly. Many drug interactions (e.g., cimetidine, fluoroquinolones, macrolides) increase levels. Smoking induces metabolism, requiring higher doses.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take exactly as prescribed; do not change dose without consulting doctor.,Do not crush or chew sustained-release capsules.,Avoid excessive caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms like nausea, vomiting, palpitations, insomnia, or seizures.,Notify doctor if you start or stop smoking, or if you are prescribed new medications.,Keep regular appointments for blood level monitoring.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOBID vs AEROLATE, answered by our medical review team.
THEOBID is a Bronchodilator that works by Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing c AMP, and blocking adenosine receptors. It also has anti-inflammatory and immunomodulatory effects.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOBID and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOBID is: Theophylline extended-release capsules: 300-600 mg/day orally divided every 12 hours. Initial dose 300 mg/day, titrate based on serum concentrations (target 10-20 mcg/m L). Max 600 mg/day unless serum levels monitored.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOBID and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOBID is classified as Category C. Theophylline (THEOBID) is not considered a major teratogen. First trimester: Limited data show no significant increase in congenital malformations. Second and third trimesters: No . AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.